title: Protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) pretreatment in STZ-induced diabetic mice.
abstract: Human glucagon-like peptide-1 (hGLP-1) and its mimetics have emerged as therapies for type 2 diabetes. However, clinical treatment of diabetes with hGLP-1 is ineffective because of rapid DPPIV-mediated hGLP-1 degradation in the circulation. In this study, we investigated the protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) treatment on STZ-induced diabetic mice. Mice were treated daily with rhGLP-1 (24 nmol/kg body weight) starting before or after STZ injection (40 mg/kg body weight) to induce diabetes. Mice pretreated with rhGLP-1 before but not after STZ showed significantly reduced blood glucose levels (P < 0.05), increased oral glucose tolerance (area under the curve, 1740 ± 71.18 vs 2416 ± 205.6, P < 0.05). Furthermore, the bioproduct of lipid peroxidation, MDA, was reduced and SOD and GSH-PX activities were enhanced globally and in pancreas of mice that received rhGLP-1 pretreatment before STZ, when comparing with STZ-treated mice. Finally, STZ-induced pancreatic islet damage was rescued by rhGLP-1 pretreatment. Taken together, the results of this study demonstrate that rhGLP-1 pretreatment has a protective effect against STZ-induced diabetes in mice. These findings suggest that the GLP-1 pretreatment may be a new therapeutic strategy in the preventive and protective treatment during diabetes initiation and progression.
authors.affiliation: School of Life Science, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China.
authors.forename: Ye-Lin
authors.initials: YL
authors.lastname: Wu
authors.forename: Jing
authors.initials: J
authors.lastname: Huang
authors.forename: Jian
authors.initials: J
authors.lastname: Liu
authors.forename: Ming-Fei
authors.initials: MF
authors.lastname: Jin
authors.forename: Mei
authors.initials: M
authors.lastname: Gu
authors.forename: Yiguo
authors.initials: Y
authors.lastname: Hong
authors.forename: Zi-Rong
authors.initials: ZR
authors.lastname: Wu
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D052216:Glucagon-Like Peptide 1 / Q000235:genetics / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006801:Humans; D051379:Mice; D018384:Oxidative Stress; D010179:Pancreas / Q000166:cytology / Q000473:pathology; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D011994:Recombinant Proteins; D052216:Glucagon-Like Peptide 1